Literature DB >> 24396259

The potential contribution of ranolazine to Torsade de Pointe.

Zhigang Liu1, Richard B Williams1, Boaz D Rosen1.   

Abstract

Ranolazine is a novel anti-anginal agent acting through pharmacologic mechanism of inhibition of the late phase of the inward sodium current. In addition, it is a potent inhibitor of rapid delayed rectifier potassium currents, leading to prolongation of the QT interval. However, ranolazine has not yet described to be associated with Torsade de Pointes despite its QT-prolonging effect. In this case report, we describe a patient on ranolazine who developed Torsade de Pointes and discuss about the potential contribution of ranolazine to the development of Torsade de Pointes.

Entities:  

Keywords:  Prolonged QT interval; Ranolazine; Torsade de Pointes

Year:  2013        PMID： 24396259      PMCID： PMC3849286          DOI： 10.1016/j.jcdr.2013.08.005

Source DB:  PubMed          Journal:  J Cardiovasc Dis Res        ISSN： 0975-3583


  15 in total

Review 1.  Long QT syndrome: diagnosis and management.

Authors:  Ijaz A Khan
Journal:  Am Heart J       Date:  2002-01       Impact factor: 4.749

2.  Drugs and the QT interval - caveat doctor.

Authors:  Barbara A Liu; David N Juurlink
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

Review 3.  Drug-induced prolongation of the QT interval.

Authors:  Dan M Roden
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

4.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death).

Authors:  Douglas P Zipes; A John Camm; Martin Borggrefe; Alfred E Buxton; Bernard Chaitman; Martin Fromer; Gabriel Gregoratos; George Klein; Arthur J Moss; Robert J Myerburg; Silvia G Priori; Miguel A Quinones; Dan M Roden; Michael J Silka; Cynthia Tracy; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Elliott M Antman; Jeffrey L Anderson; Sharon A Hunt; Jonathan L Halperin; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; A John Camm; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; Juan Luis Tamargo; José Luis Zamorano
Journal:  J Am Coll Cardiol       Date:  2006-09-05       Impact factor: 24.094

Review 5.  Clinical practice. Long-QT syndrome.

Authors:  Dan M Roden
Journal:  N Engl J Med       Date:  2008-01-10       Impact factor: 91.245

6.  Treatment of torsade de pointes with magnesium sulfate.

Authors:  D Tzivoni; S Banai; C Schuger; J Benhorin; A Keren; S Gottlieb; S Stern
Journal:  Circulation       Date:  1988-02       Impact factor: 29.690

7.  Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence.

Authors:  L M Hondeghem; D J Snyders
Journal:  Circulation       Date:  1990-02       Impact factor: 29.690

8.  Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.

Authors:  David A Morrow; Benjamin M Scirica; Ewa Karwatowska-Prokopczuk; Sabina A Murphy; Andrzej Budaj; Sergei Varshavsky; Andrew A Wolff; Allan Skene; Carolyn H McCabe; Eugene Braunwald
Journal:  JAMA       Date:  2007-04-25       Impact factor: 56.272

Review 9.  Ranolazine: clinical applications and therapeutic basis.

Authors:  Nael Hawwa; Venu Menon
Journal:  Am J Cardiovasc Drugs       Date:  2013-02       Impact factor: 3.571

Review 10.  Torsade de pointes.

Authors:  Nabil El-Sherif; Gioia Turitto
Journal:  Curr Opin Cardiol       Date:  2003-01       Impact factor: 2.161
View more
  3 in total

1.  Early afterdepolarisation tendency as a simulated pro-arrhythmic risk indicator.

Authors:  Beth McMillan; David J Gavaghan; Gary R Mirams
Journal:  Toxicol Res (Camb)       Date:  2017-09-14       Impact factor: 3.524

2.  Inhibition of voltage-gated Na+ currents by eleclazine in rat atrial and ventricular myocytes.

Authors:  Rachel E Caves; Alexander Carpenter; Stéphanie C Choisy; Ben Clennell; Hongwei Cheng; Cameron McNiff; Brendan Mann; James T Milnes; Jules C Hancox; Andrew F James
Journal:  Heart Rhythm O2       Date:  2020-08

Review 3.  Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning.

Authors:  Sarah Rouhana; Anne Virsolvy; Nassim Fares; Sylvain Richard; Jérôme Thireau
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.